PTC Therapeutics (PTCT) Stock Forecast & Price Target

Compare

395 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTCT Analyst Ratings

Moderate Buy

11 Buy

5 Hold

1 Sell

Based on 17 analysts giving stock ratings to

PTC

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTCT Stock 12 Month Forecast

Average Price Target

$66.81

▲(32.11% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $66.81 with a high forecast of $120.00 and a low forecast of $44.00. The average price target represents a 32.11% change from the last price of $50.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"$31","76":"$76","121":"$121","53.5":"$53.5","98.5":"$98.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,53.5,76,98.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.13,57.35076923076923,62.571538461538466,67.7923076923077,73.01307692307692,78.23384615384616,83.45461538461538,88.67538461538462,93.89615384615385,99.11692307692309,104.33769230769232,109.55846153846154,114.77923076923076,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.13,53.25923076923077,54.38846153846154,55.51769230769231,56.64692307692308,57.776153846153846,58.90538461538462,60.034615384615385,61.16384615384616,62.293076923076924,63.4223076923077,64.55153846153847,65.68076923076923,{"y":66.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.13,51.504615384615384,50.87923076923077,50.253846153846155,49.62846153846154,49.003076923076925,48.37769230769231,47.752307692307696,47.12692307692308,46.50153846153846,45.87615384615385,45.25076923076923,44.62538461538462,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$66.81

Lowest Price Target$44.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tiago Fauth

Wells Fargo

$79→$73

Buy

44.35%

Upside

Reiterated

08/20/25

PTC Therapeutics price target lowered to $73 from $79 at Wells FargoPTC Therapeutics price target lowered to $73 from $79 at Wells Fargo

Judah Frommer

Morgan Stanley

$76→$71

Buy

40.40%

Upside

Reiterated

08/20/25

Analysts Are Bullish on These Healthcare Stocks: Myriad Genetics (MYGN), PTC Therapeutics (PTCT)

Joon Lee

Truist Financial

$86

Buy

70.06%

Upside

Reiterated

08/19/25

Truist Financial Keeps Their Buy Rating on PTC Therapeutics (PTCT)

Joseph Schwartz

Leerink Partners

$54

Hold

6.78%

Upside

Reiterated

08/19/25

PTC Therapeutics (PTCT) Receives a Hold from Leerink Partners

Paul Choi

Goldman Sachs

$44

Sell

-12.99%

Downside

Reiterated

08/19/25

PTC Therapeutics (PTCT) Receives a Sell from Goldman SachsGoldman Sachs analyst Paul Choi reiterated a Sell rating and $44.00 price target on PTC Therapeutics (NASDAQ: PTCT).

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/19/25

PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback

Kelly Shi

Jefferies

$64→$63

Buy

24.58%

Upside

Reiterated

08/19/25

PTC Therapeutics price target lowered to $63 from $64 at JefferiesPTC Therapeutics price target lowered to $63 from $64 at Jefferies

Brian Abrahams

RBC Capital

$63

Buy

24.58%

Upside

Reiterated

08/19/25

PTC Therapeutics CRL 'expected,' focus moves to Sephience, says RBC CapitalPTC Therapeutics CRL 'expected,' focus moves to Sephience, says RBC Capital

Joseph Thome

TD Cowen

$56→$50

Hold

-1.13%

Downside

Reiterated

08/19/25

PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential

Tazeen Ahmad

Bank of America Securities

$82→$76

Buy

50.29%

Upside

Reiterated

08/19/25

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Brian Cheng

J.P. Morgan

$68

Buy

34.47%

Upside

Reiterated

08/19/25

PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline

Joel Beatty

Robert W. Baird

$72→$70

Buy

38.42%

Upside

Reiterated

08/08/25

PTC Therapeutics price target lowered to $70 from $72 at BairdPTC Therapeutics price target lowered to $70 from $72 at Baird

Gena Wang

Barclays

$46

Hold

-9.04%

Downside

Reiterated

08/08/25

Barclays Sticks to Their Hold Rating for PTC Therapeutics (PTCT)

Eliana Merle

UBS

$71→$80

Buy

58.20%

Upside

Reiterated

07/30/25

PTC Therapeutics price target raised to $80 from $71 at UBSPTC Therapeutics price target raised to $80 from $71 at UBS

Kristen Kluska

Cantor Fitzgerald

$112→$120

Buy

137.29%

Upside

Reiterated

07/29/25

PTC Therapeutics (PTCT) Gets a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $120.00 (from $112.00) while maintaining an Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tiago Fauth

Wells Fargo

$79→$73

Buy

44.35%

Upside

Reiterated

08/20/25

PTC Therapeutics price target lowered to $73 from $79 at Wells FargoPTC Therapeutics price target lowered to $73 from $79 at Wells Fargo

Judah Frommer

Morgan Stanley

$76→$71

Buy

40.40%

Upside

Reiterated

08/20/25

Analysts Are Bullish on These Healthcare Stocks: Myriad Genetics (MYGN), PTC Therapeutics (PTCT)

Joon Lee

Truist Financial

$86

Buy

70.06%

Upside

Reiterated

08/19/25

Truist Financial Keeps Their Buy Rating on PTC Therapeutics (PTCT)

Joseph Schwartz

Leerink Partners

$54

Hold

6.78%

Upside

Reiterated

08/19/25

PTC Therapeutics (PTCT) Receives a Hold from Leerink Partners

Paul Choi

Goldman Sachs

$44

Sell

-12.99%

Downside

Reiterated

08/19/25

PTC Therapeutics (PTCT) Receives a Sell from Goldman SachsGoldman Sachs analyst Paul Choi reiterated a Sell rating and $44.00 price target on PTC Therapeutics (NASDAQ: PTCT).

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/19/25

PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback

Kelly Shi

Jefferies

$64→$63

Buy

24.58%

Upside

Reiterated

08/19/25

PTC Therapeutics price target lowered to $63 from $64 at JefferiesPTC Therapeutics price target lowered to $63 from $64 at Jefferies

Brian Abrahams

RBC Capital

$63

Buy

24.58%

Upside

Reiterated

08/19/25

PTC Therapeutics CRL 'expected,' focus moves to Sephience, says RBC CapitalPTC Therapeutics CRL 'expected,' focus moves to Sephience, says RBC Capital

Joseph Thome

TD Cowen

$56→$50

Hold

-1.13%

Downside

Reiterated

08/19/25

PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential

Tazeen Ahmad

Bank of America Securities

$82→$76

Buy

50.29%

Upside

Reiterated

08/19/25

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

Brian Cheng

J.P. Morgan

$68

Buy

34.47%

Upside

Reiterated

08/19/25

PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline

Joel Beatty

Robert W. Baird

$72→$70

Buy

38.42%

Upside

Reiterated

08/08/25

PTC Therapeutics price target lowered to $70 from $72 at BairdPTC Therapeutics price target lowered to $70 from $72 at Baird

Gena Wang

Barclays

$46

Hold

-9.04%

Downside

Reiterated

08/08/25

Barclays Sticks to Their Hold Rating for PTC Therapeutics (PTCT)

Eliana Merle

UBS

$71→$80

Buy

58.20%

Upside

Reiterated

07/30/25

PTC Therapeutics price target raised to $80 from $71 at UBSPTC Therapeutics price target raised to $80 from $71 at UBS

Kristen Kluska

Cantor Fitzgerald

$112→$120

Buy

137.29%

Upside

Reiterated

07/29/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PTC Therapeutics

1 Month

xxx

Success Rate

14/18 ratings generated profit

Average Return

+7.23%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +7.23% per trade.

3 Months

xxx

Success Rate

14/18 ratings generated profit

Average Return

+12.89%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +12.89% per trade.

1 Year

Joel BeattyRobert W. Baird

Success Rate

16/18 ratings generated profit

Average Return

+37.76%

reiterated a buy rating 16 days ago

Copying Joel Beatty's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +37.76% per trade.

2 Years

xxx

Success Rate

16/18 ratings generated profit

Average Return

+55.24%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +55.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTCT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTCT has received 37 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. PTCT average Analyst price target in the past 3 months is 66.81.

Each month's total comprises the sum of three months' worth of ratings.

PTCT Financial Forecast

PTCT Earnings Forecast

Next quarter’s earnings estimate for PTCT is -$1.02 with a range of -$1.67 to $0.57. The previous quarter’s EPS was -$0.83. PTCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Sales Forecast

Next quarter’s sales forecast for PTCT is $183.50M with a range of $140.30M to $314.85M. The previous quarter’s sales results were $178.88M. PTCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?

Based on analyst ratings, PTC Therapeutics’s 12-month average price target is 66.81.

What is PTCT’s upside potential, based on the analysts’ average price target?

PTC Therapeutics has 32.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTCT a Buy, Sell or Hold?

PTC Therapeutics has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 1 sell ratings.

What is PTC Therapeutics’s price target?

The average price target for PTC Therapeutics is 66.81. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $44.00. The average price target represents 32.11% Increase from the current price of $50.57.

What do analysts say about PTC Therapeutics?

PTC Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of PTCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTCT Analyst Ratings

PTCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PTC Therapeutics

PTCT Analyst Recommendation Trends

PTCT Financial Forecast

PTCT Earnings Forecast

PTCT Sales Forecast

PTCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts